Chemistry:AB-300

From HandWiki

AB-300, short for Ariadne Bio-300, is a non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist which is under development for potential medical use to treat non-motor symptoms of Parkinson's disease such as apathy and motivational deficits as well as late-life depression.[1][2][3]

It has been found to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine and hence to produce pro-motivational effects in rodents.[1] These effects were more pronounced in rodents with the lowest baseline motivation and were comparable to those of the norepinephrine–dopamine reuptake inhibitor (NDRI) bupropion.[1] Bupropion has psychostimulant-like effects in rodents, but not at typical clinical doses in humans.[4][5][6]

AB-300 is under development by Ariadne Bio, a company of Negev Labs.[1][2][3] Ariadne Bio is named after Ariadne (4C-D; BL-3912; Dimoxamine), a non-hallucinogenic serotonin 5-HT2A receptor agonist which was developed by Alexander Shulgin and Bristol Laboratories, produced indirect dopaminergic and pro-motivational effects in animals analogously to AB-300, and reached phase 3 clinical trials for various medical uses in the 1970s, but was ultimately never marketed due to cited strategic economic reasons.[7][8][9][10] A phase 1b trial of AB-300 is initiating in the third quarter of 2026.[2][3] The exact chemical structure of AB-300 does not yet appear to have been disclosed, but it is said to have been patented.[1][2]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "AB-300, a novel 5-HT2A/2C agonist, reverses motivational deficits in a tetrabenazine model of Parkinson's disease apathy". 2026 ASCP Annual Meeting. Miami Beach, Florida: American Society of Clinical Psychopharmacology. May 2026. https://cnspulse.com/abstracts/132-ab-300-a-novel-5-ht2a-2c-agonist-reverses-motivational-defic/. Retrieved 9 August 2026. 
  2. ↑ 2.0 2.1 2.2 2.3 "Ariadne Bio". https://ariadnebio.com/. "Ariadne Bio is the first company from Negev Labs, [...] AB-300 is designed to activate 5-HT2A without hallucinogenic effect, potentially making it an accessible and self-administered therapy for motivational deficits. [...] Patented. Randomized, placebo-controlled Phase 1b trial in Parkinson's disease patients with clinically significant apathy. [...] Phase 1b clinical trial initiating Q3 2026" 
  3. ↑ 3.0 3.1 3.2 Negev Labs. "CNS & Brain Health Therapeutics Venture Fund". https://negevcap.com/. "Ariadne Bio is developing AB-300, a first-in-class non-hallucinogenic 5-HT2A agonist designed to treat apathy in Parkinson's disease, late-life depression, and neurodegeneration [...] Phase 1b trial initiation targeted for Q3 2026. [...] Stage Preclinical → Phase 1b Q3 2026 · Modality Non-hallucinogenic 5-HT2A agonist · Indication Apathy in Parkinson's / late-life depression" 
  4. ↑ "Comparison of the behavioral effects of bupropion and psychostimulants". European Journal of Pharmacology 718 (1–3): 370–375. October 2013. doi:10.1016/j.ejphar.2013.07.046. PMID 23993950. 
  5. ↑ "Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential". The American Journal of Drug and Alcohol Abuse 45 (4): 341–354. 2019. doi:10.1080/00952990.2018.1545023. PMID 30601027. 
  6. ↑ "Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent". CNS Drug Reviews 12 (3–4): 178–207. 2006. doi:10.1111/j.1527-3458.2006.00178.x. PMID 17227286. 
  7. ↑ "Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs". ACS Chemical Neuroscience 14 (1): 119–135. January 2023. doi:10.1021/acschemneuro.2c00597. PMID 36521179. 
  8. ↑ Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. http://www.erowid.org/library/books_online/pihkal/pihkal.shtml. 
  9. ↑ "#7. ARIADNE". The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. 1. Berkeley, CA: Transform Press. 2011. pp. 7–9. ISBN 978-0-9630096-3-0. OCLC 709667010. https://archive.org/details/shulgin-index-vol-1/page/7/mode/1up. 
  10. ↑ "The "Social-Chemistry" of Pharmacological Discovery: Interview with Dr. Alexander T. Shulgin. January 26, 1986". Social Pharmacology 1 (3): 279–290. 1987. https://bibliography.maps.org/resources/download/9052. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:AB-300&oldid=4644781"